For research use only. Not for therapeutic Use.
Gavestinel(CAT: M100289), also known as (S)-5-Fluoro-3-(2-methylphenyl)-2,4-imidazolidinedione, is a non-competitive antagonist of the NMDA (N-methyl-D-aspartate) receptor. By inhibiting NMDA receptor activity, Gavestinel plays a role in reducing excitotoxicity, which is a pathological process involved in neurological diseases. It has been studied for its potential neuroprotective effects, particularly in conditions like stroke, traumatic brain injury, and neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease. Gavestinel is relevant for Neurological Disease Research, offering insights into therapeutic strategies for conditions involving excessive glutamate signaling and neuronal damage.
| CAS Number | 153436-22-7 |
| Synonyms | 3-[(E)-3-anilino-3-oxoprop-1-enyl]-4,6-dichloro-1H-indole-2-carboxylic acid |
| Molecular Formula | C18H12Cl2N2O3 |
| Purity | ≥95% |
| IUPAC Name | 3-[(E)-3-anilino-3-oxoprop-1-enyl]-4,6-dichloro-1H-indole-2-carboxylic acid |
| InChI | InChI=1S/C18H12Cl2N2O3/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11/h1-9,22H,(H,21,23)(H,24,25)/b7-6+ |
| InChIKey | WZBNEZWCNKUOSM-VOTSOKGWSA-N |
| SMILES | C1=CC=C(C=C1)NC(=O)C=CC2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O |
